Smoking, citrullination and genetic variability in the immunopathogenesis of rheumatoid arthritis

Seminars in Immunology

Volumn 23, Issue 2, 2011, Pages 92-98

  Klareskog, Lars ^a   Malmström, Vivianne ^a   Lundberg, Karin ^a   Padyukov, Leonid ^a   Alfredsson, Lars ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Anti CCP; Autoimmunity; Citrullination; Gene environment interaction; HLA; Rheumatoid arthritis; Smoking

Indexed keywords

AUTOIMMUNITY; CITRULLINATION; ENVIRONMENTAL FACTOR; GENETIC EPIDEMIOLOGY; GENETIC RISK; GENETIC VARIABILITY; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; IMMUNOREGULATION; NONHUMAN; PROTEIN PROCESSING; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SMOKING;

ANIMALS; ARTHRITIS, RHEUMATOID; CITRULLINE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; SMOKING;

EID: 79953162113     PISSN: 10445323     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.smim.2011.01.014     Document Type: Review

References (72)

1. Holmdahl R. The use of animal models for rheumatoid arthritis. Methods Mol Med 2007, 136:185-189.
2. Trentham D.E., Townes A.S., Kang A.H. Autoimmunity to type II collagen an experimental model of arthritis. J Exp Med 1977, 146(September (3)):857-868.
3. Carlsén S., Hansson A.S., Olsson H., Heinegård D., Holmdahl R. Cartilage oligomeric matrix protein (COMP)-induced arthritis in rats. Clin Exp Immunol 1998, 114(December (3)):477-484.
4. Glant T.T., Mikecz K., Arzoumanian A., Poole A.R. Proteoglycan-induced arthritis in BALB/c mice. Clinical features and histopathology. Arthritis Rheum 1987, 30(February (2)):201-212.
5. Kouskoff V., Korganow A.S., Duchatelle V., Degott C., Benoist C., Mathis D. Organ-specific disease provoked by systemic autoimmunity. Cell 1996, 87(November (5)):811-822.
6. Pearson C.M. Development of arthritis, periarthritis and periostitis in rats given adjuvants. Proc Soc Exp Biol Med 1956, 91(January (1)):95-101.
7. Kleinau S., Erlandsson H., Holmdahl R., Klareskog L. Adjuvant oils induce arthritis in the DA rat. I. Characterization of the disease and evidence for an immunological involvement. J Autoimmun 1991, 4(December (6)):871-880.
8. Keffer J., Probert L., Cazlaris H., Georgopoulos S., Kaslaris E., Kioussis D., et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991, 10(December (13)):4025-4031.
9. Horai R., Saijo S., Tanioka H., Nakae S., Sudo K., Okahara A., et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 2000, 191(January (2)):313-320.
10. Plows D., Kontogeorgos G., Kollias G. Mice lacking mature T and B lymphocytes develop arthritic lesions after immunization with type II collagen. J Immunol 1999, 162(January (2)):1018-1023.
11. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31(March (3)):315-324.
12. Aletaha D., Neogi T., Silman A.J., Funovits J., Felson D.T., Bingham C.O., et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010, 62(September (9)):2569-2581.
13. Stastny P. Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. N Engl J Med 1978, 298(April (16)):869-871.
14. Gregersen P.K., Silver J., Winchester R.J. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987, 30(November (11)):1205-1213.
15. Klareskog L., Forsum U., Scheynius A., Kabelitz D., Wigzell H. Evidence in support of a self-perpetuating HLA-DR-dependent delayed-type cell reaction in rheumatoid arthritis. Proc Natl Acad Sci USA 1982, 79(June (11)):3632-3636.
16. Begovich A.B., Carlton V.E., Honigberg L.A., Schrodi S.J., Chokkalingam A.P., Alexander H.C., et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 2004, 75(August (2)):330-337.
17. The Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007;447(June):661-78.
18. Plenge R.M., Seielstad M., Padyukov L., Lee A.T., Remmers E.F., Ding B., et al. TRAF1-C5 as a risk locus for rheumatoid arthritis-a genomewide study. N Engl J Med 2007, 357(September (12)):1199-1209.
19. Remmers E.F., Plenge R.M., Lee A.T., Graham R.R., Hom G., Behrens T.W., et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007, 357(September (10)):977-986.
20. Stahl E.A., Raychaudhuri S., Remmers E.F., Xie G., Eyre S., Thomson B.P., et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 2010, 42(June (6)):508-514.
21. Waaler E. On the occurrence of a factor in human serum activating the specific agglutintion of sheep blood corpuscles. Acta Path Microbiol Scand 1940, 17:172-188.
22. Schellekens G.A., de Jong B.A., van den Hoogen F.H., van de Putte L.B., van Venrooij W.J. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998, 101(January (1)):273-281.
23. de Vries-Bouwstra J.K., Goekoop-Ruiterman Y.P., Verpoort K.N., Schreuder G.M., Ewals J.A., Terwiel J.P., et al. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies. Arthritis Rheum 2008, 58(May (5)):1293-1298.
24. van Dongen H., van Aken J., Lard L.R., Visser K., Ronday H.K., Hulsmans H.M., et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2007, 56(May (5)):1424-1432.
25. Thurlings R.M., Vos K., Wijbrandts C.A., Zwinderman A.H., Gerlag D.M., Tak P.P. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis 2008, 67(July (7)):917-925.
26. Klareskog L., Stolt P., Lundberg K., Källberg H., Bengtsson C., Grunewald J., et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006, 54(January (1)):38-46.
27. van der Helm-van Mil A.H., Huizinga T.W., de Vries R.R., Toes R.E. Emerging patterns of risk factor make-up enable subclassification of rheumatoid arthritis. Arthritis Rheum 2007, 56(June (6)):1728-1735.
28. Ding B., Padyukov L., Lundström E., Seielstad M., Plenge R.M., Oksenberg J.R., et al. Different patterns of associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in the extended major histocompatibility complex region. Arthritis Rheum 2009, 60(January (1)):30-38.
29. Lee H.S., Lee A.T., Criswell L.A., Seldin M.F., Amos C.I., Carulli J.P., et al. Several regions in the major histocompatibility complex confer risk for anti-CCP-antibody positive rheumatoid arthritis, independent of the DRB1 locus. Mol Med 2008, 14(May-June (5-6)):293-300.
30. Plenge R.M., Padyukov L., Remmers E.F., Purcell S., Lee A.T., Karlson E.W., et al. Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am J Hum Genet 2005, 77(December (6)):1044-1060.
31. Källberg H., Padyukov L., Plenge R.M., Rönnelid J., Gregersen P.K., van der Helm-van Mil A.H., et al. Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet 2007, 80(May (5)):867-875.
32. Sigurdsson S., Padyukov L., Kurreeman F.A., Liljedahl U., Wiman A.C., Alfredsson L., et al. Association of a haplotype in the promoter region of the interferon regulatory factor 5 gene with rheumatoid arthritis. Arthritis Rheum 2007, 56(July (7)):2202-2210.
33. Padyukov L., Seielstad M., Ong R.T.H., Ding B., Rönnelid J., Seddighzadeh M., et al. A genome-wide association study suggests contrasting associations in ACPA positive vs. ACPA negative rheumatoid arthritis. Ann Rheum Dis 2011, 70(February (2)):259-265.
34. Pedersen M., Jacobsen S., Garred P., Madsen H.O., Klarlund M., Svejgaard A., et al. Strong combined gene-environment effects in anti-cyclic citrullinated peptide-positive rheumatoid arthritis: a nationwide case-control study in Denmark. Arthritis Rheum 2007, 56(May (5)):1446-1453.
35. Morgan A.W., Thomson W., Martin S.G. Yorkshire Early Arthritis Register Consortium, Carter AM; UK Rheumatoid Arthritis Genetics Consortium Re-evaluation of the interaction between HLA-DRB1 shared epitope alleles, PTPN22, and smoking in determining susceptibility to autoantibody-positive and autoantibody-negative rheumatoid arthritis in a large UK Caucasian population. Arthritis Rheum 2009, 60(September (9)):2565-2576.
36. Karlson E.W., Chang S.C., Cui J., Chibnik L.B., Fraser P.A., De Vivo I., et al. Gene-environment interaction between HLA-DRB1 shared epitope and heavy cigarette smoking in predicting incident rheumatoid arthritis. Ann Rheum Dis 2010, 69(January (1)):54-60.
37. van der Helm-van Mil A.H., Verpoort K.N., le Cessie S., Huizinga T.W., de Vries R.R., Toes R.E. The HLA-DRB1 shared epitope alleles differ in the interaction with smoking and predisposition to antibodies to cyclic citrullinated peptide. Arthritis Rheum 2007, 56(February (2)):425-432.
38. Rothman K.J. Causes. Am J Epidemiol 1976, 104:587-592.
39. Rothman K.J. Epidemiology. An introduction 2002, Oxford University Press, New York.
40. VanderWeele T.J. Sufficient cause interactions and statistical interactions. Epidemiology 2009, 20:6-13.
41. Rothman K.J., Greenland S., Lash T.L. Modern epidemiology 2008, Lippincott Williams and Wilkins, Philadelphia.
42. Makrygiannakis D., Hermansson M., Ulfgren A.K., Nicholas A.P., Zendman A.J., Eklund A., et al. Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann Rheum Dis 2008, 67(October (10)):1488-1492.
43. Stolt P., Yahya A., Bengtsson C., Källberg H., Rönnelid J., Lundberg I., et al. Silica exposure among male current smokers is associated with a high risk of developing ACPA-positive rheumatoid arthritis. Ann Rheum Dis 2010, 69(June (6)):1072-1076.
44. Baeten D., Peene I., Union A., Meheus L., Sebbag M., Serre G., et al. Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium: relevance to antifilaggrin autoantibodies. Arthritis Rheum 2001, 44(October (10)):2255-2262.
45. Chang X., Yamada R., Suzuki A., Sawada T., Yoshino S., Tokuhiro S., et al. Localization of peptidylarginine deiminase 4 (PADI4) and citrullinated protein in synovial tissue of rheumatoid arthritis. Rheumatology (Oxford) 2005, 44(January (1)):40-50.
46. Klareskog L., Rönnelid J., Lundberg K., Padyukov L., Alfredsson L. Immunity to citrullinated proteins in rheumatoid arthritis. Annu Rev Immunol 2008, 26:651-675.
47. Sebbag M., Moinard N., Auger I., Clavel C., Arnaud J., Nogueira L., et al. Epitopes of human fibrin recognized by the rheumatoid arthritis-specific autoantibodies to citrullinated proteins. Eur J Immunol 2006, 36(August (8)):2250-2263.
48. Vossenaar E.R., Després N., Lapointe E., van der Heijden A., Lora M., Senshu T., et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 2004, 6(2):R142-R150.
49. Burkhardt H., Sehnert B., Bockermann R., Engström A., Kalden J.R., Holmdahl R. Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis. Eur J Immunol 2005, 35(May (5)):1643-1652.
50. Kinloch A., Tatzer V., Wait R., Peston D., Lundberg K., Donatien P., et al. Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther 2005, 7(6):R1421-R1429.
51. Lundberg K., Kinloch A., Fisher B.A., Wegner N., Wait R., Charles P., et al. Antibodies to citrullinated alpha-enolase peptide 1 are specific for rheumatoid arthritis and cross-react with bacterial enolase. Arthritis Rheum 2008, 58(October (10)):3009-3019.
52. Snir O., Widhe M., von Spee C., Lindberg J., Padyukov L., Lundberg K., et al. Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 alleles. Ann Rheum Dis 2009, 68(May (5)):736-743.
53. Snir O., Widhe M., Hermansson M., von Spee C., Lindberg J., Hensen S., et al. Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients. Arthritis Rheum 2010, 62(January (1)):44-52.
54. Mahdi H., Fisher B.A., Källberg H., Plant D., Malmström V., Rönnelid J., et al. Specific interaction between genotype, smoking and autoimmunity to citrullinated alpha-enolase in the etiology of rheumatoid arthritis. Nat Genet 2009, 41(December (12)):1319-1324.
55. van der Woude D., Alemayehu W.G., Verduijn W., de Vries R.R., Houwing-Duistermaat J.J., Huizinga T.W., et al. Gene-environment interaction influences the reactivity of autoantibodies to citrullinated antigens in rheumatoid arthritis. Nat Genet 2010, 42(October (10)):814-816.
56. Hill J.A., Southwood S., Sette A., Jevnikar A.M., Bell D.A., Cairns E. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 2003, 171(July (2)):538-541.
57. Feitsma A.L., van der Voort E.I., Franken K.L., el Bannoudi H., Elferink B.G., Drijfhout J.W., et al. Identification of citrullinated vimentin peptides as T cell epitopes in HLA-DR4-positive patients with rheumatoid arthritis. Arthritis Rheum 2010, 62(January (1)):117-125.
58. Aho K., Palosuo T., Heliövaara M., Knekt P., Alha P., von Essen R. Filaggrin antibodies within " normal" range predict rheumatoid arthritis in a linear fashion. J Rheumatol 2000, 27(December (12)):2743-2746.
59. Rantapää-Dahlqvist S., de Jong B.A., Berglin E., Hallmans G., Wadell G., Stenlund H., et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003, 48(October (10)):2741-2749.
60. Nielen M.M., van Schaardenburg D., Reesink H.W., van de Stadt R.J., van der Horst-Bruinsma I.E., de Koning M.H., et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004, 50(February (2)):380-386.
61. van de Stadt L.A., van der Horst A.R., de Koning M.H., Bos W.H., Wolbink G.J., van de Stadt, et al. The extent of the anti-citrullinated protein antibody repertoire is associated with arthritis development in patients with seropositive arthralgia. Ann Rheum Dis 2011, 70(January (1)):128-133.
62. van der Woude D., Rantapää-Dahlqvist S., Ioan-Facsinay A., Onnekink C., Schwarte C.M., Verpoort K.N., et al. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann Rheum Dis 2010, 69(August (8)):1554-1561.
63. Kokkonen H., Söderström I., Rocklöv J., Hallmans G., Lejon K., Rantapää-Dahlqvist S. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum 2010, 62(February (2)):383-391.
64. Klareskog L., Catrina A.I., Paget S. Rheumatoid arthritis. Lancet 2009, 373(February (9664)):659-672.
65. Lundberg K., Nijenhuis S., Vossenaar E.R., Palmblad K., van Venrooij W.J., Klareskog L., et al. Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res Ther 2005, 7(3):R458-R467.
66. Hill J.A., Bell D.A., Brintnell W., Yue D., Wehrli B., Jevnikar A.M., et al. Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice. J Exp Med 2008, 205(April (4)):967-979.
67. Uysal H., Bockermann R., Nandakumar K.S., Sehnert B., Bajtner E., Engström A., et al. Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis. J Exp Med 2009, 206(February (2)):449-462.
68. Kuhn K.A., Kulik L., Tomooka B., Braschler K.J., Arend W.P., Robinson W.H., et al. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest 2006, 116(April (4)):961-973.
69. Caplan A. Rheumatoid disease and pneumoconiosis (Caplan's syndrome). Proc R Soc Med 1959, 52(December):1111-1113.
70. Hart J.E., Laden F., Puett R.C., Costenbader K.H., Karlson E.W. Exposure to traffic pollution and increased risk of rheumatoid arthritis. Environ Health Perspect 2009, 117(July (7)):1065-1069.
71. Mikuls T.R., Payne J.B., Reinhardt R.A., Thiele G.M., Maziarz E., Cannella A.C., et al. Antibody responses to Porphyromonas gingivalis (P. gingivalis) in subjects with rheumatoid arthritis and periodontitis. Int Immunopharmacol 2009, 9(January (1)):38-42.
72. Lundberg K., Wegner N., Yucel-Lindberg T., Venables P.J. Periodontitis in RA-the citrullinated enolase connection. Nat Rev Rheumatol 2010, 6(December (12)):727-730.